Sanofi: Sanofi and Alnylam conclude research and option phase of 2014 rare disease alliance
08 Abril 2019 - 12:00AM
Sanofi and Alnylam conclude
research and option phase of 2014 rare disease
alliance
Paris - April 8, 2019 - Sanofi and Alnylam
have agreed to conclude the research and option phase of the
companies' 2014 RNAi therapeutics alliance in rare genetic
diseases. The material collaboration terms for patisiran,
vutrisiran (ALN-TTRsc02) and fitusiran, as previously announced,
will continue unchanged.
As part of this agreement, Alnylam
will advance an additional investigational asset in an undisclosed
rare genetic disease through the end of IND-enabling studies.
Sanofi will be responsible for any potential further development or
commercialization of such asset. If this product is approved,
Alnylam will be eligible to receive tiered double-digit royalties
on its global net sales.
"Our
alliance with Alnylam has successfully brought one important
medicine to patients with ATTR amyloidosis and it also has spawned
a molecule that is in pivotal clinical trials for people with
hemophilia," said John Reed, Global Head of Research and
Development at Sanofi. "As we wrap up this phase
of our program with Alnylam, we remain committed to advancing
therapies for patients with rare diseases and rare blood
disorders."
In addition, Alnylam and Sanofi
have agreed to amend certain terms of the companies' equity
agreement, with Sanofi obtaining a release of its lock-up of
Alnylam stock holdings, subject to certain trading restrictions,
amongst other provisions.
About Sanofi
Sanofi is dedicated to supporting people through their health
challenges. We are a global biopharmaceutical company focused on
human health. We prevent illness with vaccines, provide innovative
treatments to fight pain and ease suffering. We stand by the few
who suffer from rare diseases and the millions with long-term
chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is
transforming scientific innovation into healthcare solutions around
the globe.
Sanofi, Empowering Life
|
Media Relations Contact Ashleigh
Koss
Tel.: +1 908 981 8745
mr@sanofi.com
|
Investor Relations Contact George
Grofik
Tel.: +33 (0)1 53 77 45 45
ir@sanofi.com
|
Sanofi Forward-Looking Statements
This press release contains forward-looking
statements as defined in the Private Securities Litigation Reform
Act of 1995, as amended. Forward-looking statements are statements
that are not historical facts. These statements include projections
and estimates and their underlying assumptions, statements
regarding plans, objectives, intentions and expectations with
respect to future financial results, events, operations, services,
product development and potential, and statements regarding future
performance. Forward-looking statements are generally identified by
the words "expects", "anticipates", "believes", "intends",
"estimates", "plans" and similar expressions. Although Sanofi's
management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned
that forward-looking information and statements are subject to
various risks and uncertainties, many of which are difficult to
predict and generally beyond the control of Sanofi, that could
cause actual results and developments to differ materially from
those expressed in, or implied or projected by, the forward-looking
information and statements. These risks and uncertainties include
among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post
marketing, decisions by regulatory authorities, such as the FDA or
the EMA, regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential
of such product candidates, the absence of guarantee that the
product candidates if approved will be commercially successful, the
future approval and commercial success of therapeutic alternatives,
Sanofi's ability to benefit from external growth opportunities, to
complete related transactions and/or obtain regulatory clearances,
risks associated with intellectual property and any related pending
or future litigation and the ultimate outcome of such
litigation, trends in exchange rates and prevailing interest
rates, volatile economic conditions, the impact of cost containment
initiatives and subsequent changes thereto, the average number of
shares outstanding as well as those discussed or identified in the
public filings with the SEC and the AMF made by Sanofi, including
those listed under "Risk Factors" and "Cautionary Statement
Regarding Forward-Looking Statements" in Sanofi's annual report on
Form 20-F for the year ended December 31, 2018. Other than as
required by applicable law, Sanofi does not undertake any
obligation to update or revise any forward-looking information or
statements.
|
Press release (PDF)
This
announcement is distributed by West Corporation on behalf of West
Corporation clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Sanofi via Globenewswire
Sanofi (EU:SAN)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Sanofi (EU:SAN)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024